STOCKHOLM, Sweden, Jan. 15, 2004 (PRIMEZONE) -- Artimplant AB, a Swedish biomaterials company, has been granted CE- certification for its Artelon(TM) Surgical Suture, i.e. approval to market the product in Europe.
The Artelon(TM) Surgical Suture, is the company's third CE-marked product based on its proprietary Artelon(TM) biomaterials technology. The suture received 510(k) clearance by the FDA in November 2003.
For additional information, please contact: Tord Lendau, CEO phone +46 (0)31 746 56 00, +46 (0)708 369 403 tord.lendau@artimplant.se Ulf Akerblom, VP Corporate Development phone +46 (0)31 746 56 00, +46 (0)709 675 999 ulf.akerblom@artimplant.se
ARTIMPLANT
Artimplant is a biomaterial company that focuses on orthopedic surgery solutions. The company runs R&D operations for biodegradable implants and develops manufacturing processes for the implants. Its goal is to enable active lives. Artimplant's biomaterial is based on a new technology that's opening new markets within orthopedic surgery and closely related areas that have extensive med-tech needs.
Artimplant developed and patented several different degradable ligament implants that are now in clinical trials. The company's business concept is to license products and technologies to global partners.
The Artimplant stock is listed on the Stockholm stock exchange's O list.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/01/15/20040115BIT00770/wkr0001.doc
http://www.waymaker.net/bitonline/2004/01/15/20040115BIT00770/wkr0002.pdf